These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 10632339)

  • 21. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
    Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
    Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
    Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
    Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
    Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
    Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
    Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
    Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors.
    Ren J; Peng Z; Yang K
    Gynecol Oncol; 2008 Aug; 110(2):162-7. PubMed ID: 18495223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
    Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
    Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
    Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
    J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
    Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
    Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
    Salvesen HB; Iversen OE; Akslen LA
    Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.